Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydromorphine SCHEMBL12402795 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL29394226 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19107002 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL13348852 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL26346 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19645038 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL13380388 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19615483 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL17025853 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL15449768 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140271835-A1 | ABUSE RESISTANT CAPSULE | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2014-09-18 | — | — | US | claimed |
| US-20100221322-A1 | Abuse-Resistant Pharmaceutical Dosage Form | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | claimed |
| US-20050186139-A1 | Abuse-proofed dosage form | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | claimed |
| US-20230330044-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11224576-B2 | Process for the production of an abuse-proofed dosage form | Grünenthal GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| EP-3824878-A1 | ABUSE RESISTANT CAPSULE | R.P. Scherer Technologies, LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200215053-A1 | ABUSE-PROOFED DOSAGE FORM | Grünenthal GmbH (DE) | 2020-07-09 | — | — | US | disclosed |
| US-10653776-B2 | Compositions and methods for reducing overdose | INTELLIPHARMACEUTICS CORP. (CA) | 2020-05-19 | — | — | US | disclosed |
| US-10610497-B2 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | ACURA PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190321358-A1 | ABUSE-PROOFED DOSAGE FORM | Grünenthal GmbH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-10420729-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-09-24 | — | — | US | disclosed |
| US-20090004267-A1 | Dosage Form with Impeded Abuse | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005408-A1 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM | GRUNENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080311049-A1 | Thermoforming by extrusion without discoloration; controlled release | GRUNENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311197-A1 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM | GRUNENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080152595-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070003616-A1 | Process for the production of an abuse-proofed dosage form | ENDO PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050249792-A1 | Active ingredient release system comprising a plaster containing an active ingredient and at least one active ingredient release regulator | GRUENENTHAL GMBH (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050186139-A1 | Abuse-proofed dosage form | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| US-20050031546-A1 | Abuse-proffed dosage form | ENDO PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |